Three well-established driver alterations in leiomyomas are MED12 mutations, chromosomal rearrangements leading to HMGA2 overexpression, and biallelic mutations resulting in FH-deficiency, which together account for 80–90% of the tumors [15]. Here, MED12 is linked to leiomyoma.